Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
A phase 3 trial of M701 run by Wuhan YZY Biopharma Co., Ltd., active.
Overview
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody is a phase 3 interventional study registered as NCT06432296 by Wuhan YZY Biopharma Co., Ltd., with 312 participants enrolled, started 2024-03-25. Conditions listed: Malignant Ascites. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors
Phase
Phase 3
Sponsor
Wuhan YZY Biopharma Co., Ltd.
Registry
Enrolled
312